Amgen

Amgen Inc.
	Headquarters in Thousand Oaks, California
Formerly	Applied Molecular Genetics (1980–1983)
Company type	Public
Traded as	Nasdaq: AMGN; Nasdaq-100 component; DJIA component; S&P 100 component; S&P 500 component;
ISIN	US0311621009
Industry	Biotechnology
Founded	April 8, 1980
Headquarters	Thousand Oaks, California, U.S.
Key people	Robert A. Bradway (chairman, president & CEO); Howard Y. Chang (CSO);
Products	Aimovig; Aranesp; Blincyto; Epogen; Kineret; Enbrel; Kyprolis; Neulasta; Neupogen; Nplate; Parsabiv; Prolia; Repatha; Sensipar/Mimpara; Vectibix; Xgeva;
Revenue	US$36.8 billion (2025)
Operating income	US$9.08 billion (2025)
Net income	US$7.71 billion (2025)
Total assets	US$90.6 billion (2025)
Total equity	US$8.66 billion (2025)
Number of employees	31,500 (2025)
Website	amgen.com
	Footnotes / references;

Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. The company is ranked 18th on the list of largest biomedical companies by revenue. The name "AMGen" is a portmanteau of the company's original name, Applied Molecular Genetics.

The company's major products are Prolia and XGEVA (Denosumab) for treatment of osteoporosis and bone diseases ($6.7 billion in total 2024 revenues), Enbrel (Etanercept) for treatment of autoimmune diseases ($3.3 billion in 2024 revenues), Repatha (evolocumab) for treatment of hyperlipidemia ($2.3 billion in 2024 revenues), Otezla (apremilast) for treatment of psoriasis and psoriatic arthritis ($2.1 billion in 2024 revenues), Tepezza (teprotumumab) to treat Graves' ophthalmopathy ($1.8 billion in 2024 revenues), Evenity (romosozumab) to treat osteoporosis ($1.5 billion in 2024 revenues), Kyprolis (carfilzomib) to treat cancer ($1.5 billion in 2024 revenues), Nplate (romiplostim) to regulate platelet production ($1.4 billion in 2024 revenues), and Aranesp (darbepoetin alfa) to stimulate erythropoiesis ($1.3 billion in 2024 revenues).

Amgen has 17 clinical programs underway in Phase III, eight in Phase II, and 19 in Phase I. Its pipeline includes MariTide, an anti-obesity medication administered once per month by injection.

The company receives approximately 80% of its revenues from sales to the three large U.S. drug wholesalers: McKesson Corporation, Cencora, and Cardinal Health.

The company is ranked 134th on the Fortune 500 and 202nd on the Forbes Global 2000.

In 2020, the company was added to the Dow Jones Industrial Average (DJIA).